Citi’s Manthey Says US Stock Outperformance Has Further to Run

Citigroup strategists led by Beata Manthey say US equity outperformance, driven by a narrow group of giant tech stocks, still has further to run. The team remains overweight the US globally and is constructive on technology, health care and materials. The note is supportive for US equities and large-cap growth leadership, but it is analyst commentary rather than a direct market catalyst.

Analysis

The important takeaway is not just “US up / rest of world down,” but that a narrower leadership tape tends to become self-reinforcing through passive flows, systematic trend-following, and buyback support in the largest index weights. That means the beta is likely to stay concentrated in mega-cap growth while the median stock continues to underperform, which is a bad setup for active managers running benchmark-aware books and a good setup for indices and options structures tied to the largest names.

Second-order winners are the enablers around AI infrastructure, software, and select health care supply chains; losers are capital-intensive cyclicals and economically sensitive segments that need broad-based earnings acceleration to re-rate. Materials being highlighted alongside tech implies the market is not purely “defensive growth” — it is also pricing in a modest reflationary tail, but that tends to lag until China or US fiscal demand visibly improves, so commodity-linked upside is likely more tactical than structural.

The risk to the view is that leadership breadth widens faster than expected if rates back up, AI capex digestion slows, or earnings revisions rotate toward cyclicals over the next 1-3 months. In that case, crowded US-large-cap positioning is vulnerable to a sharp factor unwind, especially if the dollar weakens and international earnings translate better. The consensus may be underestimating how fragile narrow outperformance becomes once the top five names stop beating by enough to offset valuation compression elsewhere.

Key Decisions for Investors

• Maintain a tactical long/short: long QQQ, short equal-weighted SPY or IWM for the next 4-8 weeks. The trade benefits if megacap leadership persists; risk/reward worsens only if breadth expands materially, which would likely show up first in equal-weight outperformance.
• Use call spreads on SMH or XLK rather than outright longs over the next 1-2 months. This expresses continued US tech leadership while capping downside if positioning is already crowded and multiple expansion stalls.
• Pair long XLV against short XLI for 1-3 months. If the market remains narrow, quality defensives with pricing power should compound while cyclical industrials remain hostage to weak breadth and delayed capex recovery.
• Treat XLB as a tactical trade only: buy on pullbacks, hold 2-6 weeks, and take profits quickly. The material tailwind is secondary and likely more sensitive to China stimulus headlines than to durable global demand improvement.
• Avoid chasing broad international beta until US leadership starts to broaden. A cleaner expression is long US large-cap growth versus EAFE or emerging markets, but keep sizing modest because any reversal in the narrow-leadership regime can be abrupt.